Nagler David 4
4 · Audentes Therapeutics, Inc. · Filed Sep 29, 2017
Insider Transaction Report
Form 4
Nagler David
SVP, HR & Corp. Affairs
Transactions
- Sale
Common Stock
2017-09-27$30.00/sh−3,750$112,500→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2017-09-27−3,750→ 37,347 totalExercise: $2.19Exp: 2025-02-04→ Common Stock (3,750 underlying) - Exercise/Conversion
Common Stock
2017-09-27$2.19/sh+3,750$8,195→ 3,750 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]The option vested as to 25% of the total shares on February 1, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 1, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.